Table 1 Demographic and baseline clinical characteristics
Characteristic | Placebo, n = 410 (%) | GV-971, n = 408 (%) | p value |
|---|---|---|---|
Age—years | 69.7 ± 8.20 | 69.6 ± 8.12 | 0.7374 [b] |
≤ 65 years | 131 (32.0%) | 132 (32.4%) | 0.9021 [c] |
> 65 years | 279 (68.0%) | 276 (67.6%) | |
Sex | 0.8242 [c] | ||
Male—no. (%) | 177 (43.2%) | 173 (42.4%) | |
Female—no. (%) | 233 (56.8%) | 235 (57.6%) | |
Han ethnicity—no. (%) | 402 (98.0%) | 398 (97.5%) | 0.6261 [c] |
Education—years | 0.7394 [c] | ||
> 6 years | 335 (81.7%) | 337 (82.6%) | |
≤ 6 years | 75 (18.3%) | 71 (17.4%) | |
APOE ε4 carrier—no. (%) | 199 (48.5%) | 214 (52.5%) | 0.2758 [c] |
MMSE score | 19.5 ± 4.5 | 19.4 ± 4.4 | 0.5795 [b] |
MMSE < 11 | 1 (0.2%) | 0 | 0.6815 [d] |
11 ≤ MMSE < 15 | 72 (17.6%) | 68 (16.7%) | |
15 ≤ MMSE ≤ 19 | 118 (28.8%) | 122 (29.9%) | |
20 ≤ MMSE ≤ 26 | 219 (53.4%) | 216 (52.9%) | |
26 < MMSE | 0 | 2 (0.5%) | |
Duration since symptom onset (months) | 31.46 ± 20.79 | 30.42 ± 20.59 | 0.6087 [b] |
ADAS-Cog12 | 20.88 ± 10.00 | 21.28 ± 10.14 | 0.5638 [b] |
ADCS-ADL | 64.2 ± 10.1 | 64.0 ± 11.2 | 0.8910 [b] |
NPI | 5.9 ± 8.6 | 5.6 ± 8.0 | 0.5651 [b] |